Legislation & Regulation

In an open letter to all US presidential candidates published Thursday in the BMJ, a group of global health care experts assert that current research regulations allow drug companies to publish incomplete and misleading results. They ask the candidates to declare whether they support improved transparency measures that would make data on drug studies publically available and open to scrutiny.

Despite the promises of two successive governments to end forced shock treatment in Ireland, unwilling patients are still being forced to undergo the therapy, according to the Sunday Independent. “Writer Ernest Hemingway, who committed suicide shortly after ECT, is reported to have said before his death: ‘It was a brilliant cure but we lost the patient.’"

Infants exposed to SSRIs and benzodiazepines during pregnancy show impaired neurologic functioning in the first month after birth, according to a new study published in the American Journal of Psychiatry. While infants exposed SSRIs alone showed neurobehavioral effects throughout the first month, those exposed to an SSRI and a benzodiazepine had more significant problems.

The first systematic investigation of the adverse effects associated with prescribing drugs “off-label” found that the common practice of using drugs for conditions for which they are not approved increases the risk of adverse effects.

In his reaction to Dr. Makari’s Opinion piece in the ‘Times, entitled Psychiatry’s Mind-Brain Problem, Dr. Nardo articulates why the legacy of NIMH director Thomas Insel is so dangerous. “He may have kept the researchers from spinning off and following some idiosyncratic path, but he did it by forcing them to follow his own idiosyncratic path.”

On November 4, the Health Subcommittee of the House Energy and Commerce (E&C) Committee marked up an amended version of the Helping Families in Mental Health Crisis Act of 2015 (H.R. 2646), introduced by Rep. Tim Murphy (R-PA) and Rep. Eddie Bernice Johnson (D-TX). However, the bill still does not reflect the voices or meet the needs of millions of Americans with lived experience of mental health conditions because the E&C Health Subcommittee failed to incorporate our recommendations.

President Obama has made it a point of his administration to attempt to integrate the science of human behavior into smarter government policies. For example, understanding how we might act irrationally can inform policies about decisions made on the free market.

In the third major verdict of its kind, drug giant Johnson & Johnson was ordered to pay a Maryland man who grew female breasts while taking the antipsychotic Risperdal. The company failed to warn doctors, patients, and regulators of the risk of abnormal breast development in young males and now faces about 5,400 lawsuits involving the drug.

The Washington Examiner reports that the manufacturer of the antipsychotic Abilify is seeking FDA approval for new digitized pills that would alert doctors if patients fail to take their drugs on schedule.

Dennis Embry, a clinical psychologist and government consultant on mental health, shares a letter he sent to congressman Murphy warning him about how he may have been misled concerning his mental health bill. “I am specifically writing you about erroneous, false information you’ve been given about the National Registry of Evidence Base Programs and Practices. That erroneous information is likely to cause serious problems, which have been withheld from you.”

For the USC Center for Health Journalism, Martha Rosenberg points out the absurdity of allowing industry funded doctors to teach classes to practitioners about psychiatric drugs. "What if the written road test drivers take were sponsored by BP or Shell and had marketing messages interspersed?"

Oryx Cohen at TruthOut explains why the "Helping Families in Mental Health Crisis Act (HR 2646) - commonly known as the 'Murphy Bill' - appears to cater more closely to the desires of pharmaceutical companies than to the actual needs of people in psychological distress, perhaps because of Murphy's connections to key lobbyists." "If the Murphy Bill is passed, psychiatric hospitals and pharmaceutical companies will reap huge financial benefits as a result of increased hospitalization and forced treatment."

From 1999 to 2012 the percentage of Americans on antidepressants increased from 6.8% to 13%, according to a report published this week by the...

The German news agency DW features a video report on whether cannabidiol, an active substance derived from marijuana, can help relieve the symptoms of schizophrenia.

New York Times columnist, Nicholas Kristof, relates the story of Andrew Francesco, a boy who began taking Ritalin at age five and died from complications with Seroquel when he was fifteen. His father, a former pharmaceutical industry executive, reveals the industry’s greed in his memoir “Overmedicated and Undertreated.” Now the industry is pushing for a first-amendment right to market its drugs for off-label uses.

The National Institute of Mental Health (NIMH) is increasingly shifting its research emphasis toward attempting to uncover biomarkers for “mental diseases,” which may have dramatic consequences for research and training in clinical psychology. In an article to be published in next month’s Professional Psychology: Research and Practice, Marvin Goldfried outlines how the shift in funding priorities for psychological research is tied to the needs of pharmaceutical companies and the biological model in psychiatry.

For those of us who have been labeled by medical model psychiatry, it is frightening to watch the wolf of social prejudice being cloaked in the guise of mental health reform. The reality for many of us is that our lives and well-being have been profoundly affected – not only by the bad science and good marketing of pharmaceutical companies - but also by a wholesale refusal to listen. The result is a mental health system that many of us do not trust to operate in good faith. The Murphy bills add fuel to this fire.

In 2014, then National Institute of Mental Health (NIMH) director, Thomas Insel, speculated that ketamine “might be the most important breakthrough in antidepressant treatment in decades.” A recent review of the research suggests that while ketamine may produce a rapid short-term improvement in depression, the effect is short-lived and the potential for addiction and dependence warrants considerable caution.

Dear Reader, I am reaching out to you in the hope that you will get this message in time to act! Even if you only have time to read the first two sentences of this blog, please click here for instructions on how you can win the hearts and minds of our federal legislators and help them understand why HR 2646 – proposed by Rep. Tim Murphy and called the Helping Families in Mental Health Crisis Act – is a bad bill

As the UK debates whether to ban smoking inside and outside of mental health hospitals, the BMJ has solicited opinion pieces on the debate for an upcoming issue. However, psychiatric survivors have come forward alleging that the BMJ refused to print their pieces unless they removed descriptions of forced treatment and coercive care.

Legislation is being advanced that would speed up the FDA’s approval process for new drugs and medical devices, according to a report by the Pacific Standard. Pharmaceutical and medical device companies have been lobbying heavily to reduce regulations and are winning over bipartisan support by attaching these measures to increased mental health funding.

The Boston Herald reports on mental health care reform bills moving through both houses of Congress. Lawmakers warn, however, “that some aspects of the legislation could create greater barriers to access mental health care for some.”

A small study of 30 participants in Germany claims that cannabis can be used to treat “ADHD” because it increases the availability of dopamine. "This then has the same effect but is a different mechanism of action than stimulants like Ritalin and dexedrine amphetamine, which act by binding to the dopamine and interfering with the metabolic breakdown of dopamine." According to the report, 22 of the 30 participants opted to discontinue their prescriptions in favor of medical marijuana.

Robert Neugeboren, who “spent most of his adult life in institutions, often subject to isolation, physical punishment and numbing medication,” was “a celebrity of sorts in the world of the mentally ill: a survivor of the horrors of mistreatment, a case history for those who point to the positive effects of kindness and talk therapy, and, perhaps most of all, the embodiment of the bottomless mystery of the human mind.”

Marcia Angell in the New York Review of Books writes about the inherent conflict in clinical trials between “the search for scientific answers," on one hand, and “the rights and welfare of human subjects,” on the other.